OBJECTIVES: Cisplatin is commonly used in the treatment of head and neck squamous cell carcinoma (HNSCC), and the repair of cisplatin-induced DNA damage involves activation of the DNA damage response protein ataxia telangiectasia and Rad3-related (ATR). Resistance to cisplatin therapy exacerbates adverse toxicities and is associated with poor outcomes. Since repair of cisplatin-induced DNA damage contributes to resistance, we hypothesized that inhibition of ATR using AZD6738, a well-tolerated and orally-bioavailable inhibitor, would enhance the sensitivity of HNSCC cells and tumors to cisplatin. MATERIALS AND METHODS: A panel of human papilloma virus-negative (HPV-) and HPV+ HNSCC cell lines were treated with cisplatin in the absence or presence of AZD6738, and effects on cell viability, colony formation, apoptosis signaling, and DNA damage were assessed. The impact of co-treatment with cisplatin plus AZD6738 on the growth of HPV- and HPV+ cell line- and patient-derived xenograft tumors was also examined. RESULTS: Inhibition of ATR with AZD6738 enhanced cisplatin-induced growth inhibition of HNSCC cell lines and tumors, in association with increased apoptosis signaling and DNA damage. Both HPV- and HPV+ models were sensitized to cisplatin by ATR inhibition. CONCLUSION: Inhibition of ATR promotes sensitization to cisplatin in preclinical in vitro and in vivo models of HPV- and HVP+ HNSCC, supporting clinical evaluation of this strategy in this disease.
OBJECTIVES:Cisplatin is commonly used in the treatment of head and neck squamous cell carcinoma (HNSCC), and the repair of cisplatin-induced DNA damage involves activation of the DNA damage response protein ataxia telangiectasia and Rad3-related (ATR). Resistance to cisplatin therapy exacerbates adverse toxicities and is associated with poor outcomes. Since repair of cisplatin-induced DNA damage contributes to resistance, we hypothesized that inhibition of ATR using AZD6738, a well-tolerated and orally-bioavailable inhibitor, would enhance the sensitivity of HNSCC cells and tumors to cisplatin. MATERIALS AND METHODS: A panel of human papilloma virus-negative (HPV-) and HPV+ HNSCC cell lines were treated with cisplatin in the absence or presence of AZD6738, and effects on cell viability, colony formation, apoptosis signaling, and DNA damage were assessed. The impact of co-treatment with cisplatin plus AZD6738 on the growth of HPV- and HPV+ cell line- and patient-derived xenograft tumors was also examined. RESULTS: Inhibition of ATR with AZD6738 enhanced cisplatin-induced growth inhibition of HNSCC cell lines and tumors, in association with increased apoptosis signaling and DNA damage. Both HPV- and HPV+ models were sensitized to cisplatin by ATR inhibition. CONCLUSION: Inhibition of ATR promotes sensitization to cisplatin in preclinical in vitro and in vivo models of HPV- and HVP+ HNSCC, supporting clinical evaluation of this strategy in this disease.
Authors: Remko Prevo; Emmanouil Fokas; Philip M Reaper; Peter A Charlton; John R Pollard; W Gillies McKenna; Ruth J Muschel; Thomas B Brunner Journal: Cancer Biol Ther Date: 2012-07-24 Impact factor: 4.742
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: Anders Näsman; Per Attner; Lalle Hammarstedt; Juan Du; Mathilda Eriksson; Geraldine Giraud; Sofie Ahrlund-Richter; Linda Marklund; Mircea Romanitan; David Lindquist; Torbjörn Ramqvist; Johan Lindholm; Pär Sparén; Weimin Ye; Hanna Dahlstrand; Eva Munck-Wikland; Tina Dalianis Journal: Int J Cancer Date: 2009-07-15 Impact factor: 7.396
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Stuart G Jarrett; Erin M Wolf Horrell; Perry A Christian; Jillian C Vanover; Mary C Boulanger; Yue Zou; John A D'Orazio Journal: Mol Cell Date: 2014-06-19 Impact factor: 19.328
Authors: E Fokas; R Prevo; J R Pollard; P M Reaper; P A Charlton; B Cornelissen; K A Vallis; E M Hammond; M M Olcina; W Gillies McKenna; R J Muschel; T B Brunner Journal: Cell Death Dis Date: 2012-12-06 Impact factor: 8.469
Authors: Alexandre André B A da Costa; Dipanjan Chowdhury; Geoffrey I Shapiro; Alan D D'Andrea; Panagiotis A Konstantinopoulos Journal: Nat Rev Drug Discov Date: 2022-10-06 Impact factor: 112.288
Authors: Ahmed Diab; Hakan Gem; Jherek Swanger; Hee Yeon Kim; Kaleb Smith; Grace Zou; Sharat Raju; Michael Kao; Matthew Fitzgibbon; Keith R Loeb; Cristina P Rodriguez; Eduardo Méndez; Denise A Galloway; Julia M Sidorova; Bruce E Clurman Journal: Proc Natl Acad Sci U S A Date: 2020-10-22 Impact factor: 11.205
Authors: Marilin S Koch; Mykola Zdioruk; Michal O Nowicki; Alec M Griffith; Estuardo Aguilar-Cordova; Laura K Aguilar; Brian W Guzik; Francesca Barone; Paul Peter Tak; Katharina Schregel; Michael S Hoetker; James A Lederer; E Antonio Chiocca; Ghazaleh Tabatabai; Sean E Lawler Journal: Mol Ther Oncolytics Date: 2022-07-31 Impact factor: 6.311
Authors: Zhibin Cui; Hadas Dabas; Brandon C Leonard; Jamie V Shiah; Jennifer R Grandis; Daniel E Johnson Journal: Cell Death Dis Date: 2021-08-06 Impact factor: 8.469